Clinical trials

Clinical trials features

• 

  HIV-positive women in clinical trials: A gap in the facts

  Sharon L Walmsley is one of a group of female physicians, experts and patient advocates who together set up Women for Positive Action, an organisation that campaigns...

  From:  HIV treatment update

• 

  START… and why the time is now

  Simon Collins of HIV i-Base looks at an important and exciting new study of when to start HIV therapy, which needs your help....

  From:  HIV treatment update

• 

  Making sense of randomised trials

  Want to know more about cutting edge treatment news but feeling blinded by science? Caroline Sabin, Professor of Medical Statistics and Epidemiology at University College London, describes...

  From:  HIV treatment update

• 

  HATIP #38, 22nd December 2004

  Combination of antibiotics as effective and safe as co-trimoxazole at preventing infections, but too expensive to use where needed? http://www.aidsmap.com/en/news/3806F479-2DCA-4701-8A30-32C79DEF1E46.asp?hp=1 A combination of the antibiotics atovaquone and...

  From:  HIV & AIDS treatment in practice

Clinical trials in your own words

• 

  Living with HIV and hep C co-infection and haemophilia

  For most people, coping with HIV is enough of a problem in itself, but when you throw in a lifetime disorder such as haemophilia, and...

  From: In your own words

Clinical trials news from aidsmap

• Low-dose stavudine study debated between South African researchers and activists

  A proposed trial of low-dose stavudine (also known as d4T) sparked a heated debate between South African researchers and activists at the opening of the first Southern African HIV Clinicians' Society Conference held in Cape Town last month. Professor ...

  11 December 2012 | Lesley Odendal

• New fixed-dose combination pills measure up to Atripla - corrected version*

  Several studies, or updates of studies, comparing newer against older drug regimens were presented at the Eleventh International Congress on Drug Therapy in HIV Infection last week. Amongst them were the 48-week results from the STAR study, an open-label ...

  20 November 2012 | Gus Cairns

• The research agenda for antiretroviral prevention – now it gets complex

  We now know that starting antiretroviral therapy early, pre-exposure prophylaxis (PrEP) and vaginal microbicides can all have an impact on HIV transmission, Victor de Gruttola told a satellite session at the International AIDS Society conference (IAS 2011) in Rome on Sunday. ...

  18 July 2011 | Roger Pebody

• Protease inhibitor monotherapy in African setting results in viral load, but not CD4, failure in the short term

  A study of protease inhibitor monotherapy in Africa has found that 25% fewer patients on monotherapy achieved an undetectable viral load than those on standard combination therapy. However, CD4 increases were the same in both groups. The study adds ...

  10 November 2010 | Gus Cairns

• Where is HIV vaccine research heading?

  Following last year’s positive result from an HIV vaccine trial in Thailand the Global HIV Vaccine Enterprise has issued a new scientific plan, calling for a speeded-up effort to test new vaccine candidates in large trials. Global HIV Vaccine Enterprise ...

  08 September 2010 | Keith Alcorn

• Imiquimod a good treatment for pre-cancerous anal lesions in men with HIV

  HIV treatment centres should screen and treat pre-cancerous anal lesions, UK investigators argue in the online edition of AIDS. They were prompted to make this suggestion by research showing that treatment with imiquimod cream resolved or downgraded high-grade pre-cancerous anal ...

  02 September 2010 | Michael Carter

• Tenofovir microbicide halves genital herpes infections and appears safe

  One of the most unexpected and exciting results of the CAPRISA trial of a successful microbicide (see aidsmap article: Microbicides can work, CAPRISA trial shows, but more trials needed before approval) was that the gel also reduced ...

  21 July 2010 | Gus Cairns

• Microbicides can work, CAPRISA trial shows, but more trials needed before approval

  “Today is the day we achieve proof of concept for microbicides,” said Professor Gita Ramjee, head of the HIV Research Unit of the South African Medical Research Council. She was opening a session at the Eighteenth International AIDS ...

  20 July 2010 | Gus Cairns

• Maraviroc potentially useful if neurological disease is present

  Maraviroc (Celsentri) may be a good option for patients with advanced HIV disease and neurocognitive impairment, a small observation study published in the online edition of AIDS suggests. Six patients took the CCR5 inhibitor as part ...

  15 July 2010 | Michael Carter

• Myriad halts HIV maturation inhibitor drug programme

  Myriad Pharmaceuticals is to halt its research programme designed to develop an HIV maturation inhibitor, the company announced on June 7th. Maturation is the last stage in the production of HIV before it buds from a human ...

  08 June 2010 | Keith Alcorn

More news

Clinical trials news selected from other sources

• UK: Are you willing to take part in research that aims to reduce your risk of HIV?

  PROUD is a two-year study to recruit gay and bisexual men across England, who will be placed at random into one of two groups. One group will use PrEP from the start of the study, and the other group will receive PrEP after 12 months.

  16 May 2013 | PROUD study, UK Medical Research Council

• Health NGO pushes for more transparency in clinical trials

  The European Commission's proposed revision on the Clinical Trials Directive is an important step forward, but does not go far enough, says the Cochrane Collaboration, a healthcare NGO which advocates more transparency in clinical trials.

  02 May 2013 | EurActiv.com

• Clinical Trials Regulation: Protect public health: Choose transparency!

  EATG joined 10 European and International Organisations representing researchers, doctors, scientists, patients and other civil society actors in a call for the inclusion of strong transparency provisions in the Clinical Trials Regulation that is under discussion at the European Parliament and Council.

  12 April 2013 | EATG

• EATG Position Paper on the Clinical Trials Regulation proposed by the European Commission

  EATG has adopted a Position Paper on the EU Clinical Trials Regulation, which is under discussion within the Council of the EU and European Parliament following the European Commission’s proposal.

  11 April 2013 | EATG

• Big pharma, big data

  From the beginning of next year, the European Medicines Agency will release all information about clinical studies submitted to it by organisations seeking authorisation for new treatments. As this deadline approaches, heated parliamentary and legal debates are raging to determine how far this new culture of open access should go.

  05 April 2013 | Financial Times

• EU new drug approval studies "have too few patients to evaluate safety"

  For medicines intended for chronic use, the number of patients studied before regulatory approval in the European Union (EU) is insufficient to properly evaluate safety and long-term efficacy, and this points to a need for new EU legislation, say researchers writing in this week's PLOS Medicine.

  22 March 2013 | Pharma Times

• Testing HIV Prevention Tools: Other Ways Up the Alley

  We need to design prevention trials that ask, “Is this test product better than nothing?” rather than, “Is this test product better than the best available prevention combination we have?”

  15 March 2013 | Poz

• Panel Urges NIH to Reduce HIV, Hep C Research on Primates

  The National Institutes of Health (NIH) should reduce its use of chimpanzees for medical research, according to an NIH-commissioned working group.

  06 February 2013 | Poz magazine news

• HIV trial under scrutiny

  A potential breakthrough in the quest to prevent HIV and AIDS has collided with sensitivities about testing expensive drugs in poor parts of the world.

  17 January 2013 | Nature.com

• Industry Funding Changes Study Results, Research Shows

  Drugs and medical devices tend to appear more beneficial in scientific papers if they were manufactured by the company that sponsored the study, showing that who pays for the clinical trial has a direct impact on the reported outcome, according to a new analysis by researchers at UCSF and the Cochrane Collaboration.

  20 December 2012 | University of California press release

More news